Immunotherapies: Exploiting the Immune System for Cancer Treatment

Cancer is a condition that has plagued humanity for thousands of years, with the first depictions dating back to ancient Egyptian times. However, not until recent decades have biological therapeutics been developed and refined enough to safely and effectively combat cancer. Three unique immunotherapies have gained traction in recent decades: adoptive T cell transfer, checkpoint inhibitors, and bivalent antibodies. Each has led to clinically approved therapies, as well as to therapies in preclinical and ongoing clinical trials. In this review, we outline the method by which these 3 immunotherapies function as well as any major immunotherapeutic drugs developed for treating a variety of cancers.

[1]  A. Sewell,et al.  CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. , 2018, Blood.

[2]  D. Davar,et al.  High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute , 2017, Journal of Immunotherapy for Cancer.

[3]  C. K. Adokoh,et al.  Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy. , 2017, Protein and peptide letters.

[4]  G. Qasaimeh,et al.  A mini-review of c-Met as a potential therapeutic target in melanoma. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  C. Hierro,et al.  Immuno-Oncology: The Third Paradigm in Early Drug Development , 2017, Targeted Oncology.

[6]  B. Sáinz,et al.  A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet , 2017, Clinical and Translational Medicine.

[7]  G. Rosen,et al.  Response to anti-PD1 therapy with nivolumab in metastatic sarcomas , 2016, Clinical Sarcoma Research.

[8]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[9]  Z. Qin,et al.  The role of HGF/c-MET signaling pathway in lymphoma , 2016, Journal of Hematology & Oncology.

[10]  I. Lowy,et al.  Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810 , 2016, Journal of Immunotherapy for Cancer.

[11]  C. Bailly,et al.  A novel antagonist anti‐cMet antibody with antitumor activities targeting both ligand‐dependent and ligand‐independent c‐Met receptors , 2016, International journal of cancer.

[12]  L. Rosen,et al.  A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer , 2016, Clinical Cancer Research.

[13]  Yu Shyr,et al.  Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade , 2016, Cancer Immunology Research.

[14]  S. Rosenberg,et al.  Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Ohmatsu,et al.  A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies , 2016, Investigational New Drugs.

[16]  F. Hirsch,et al.  Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer , 2016, Cancer science.

[17]  L. Garraway,et al.  Abstract 3576: Broad analysis of recurrent somatic mutations in cancer reveals a common novel non-coding mutation in the promoter of PMS2 associated with greatly increased tumor mutation load , 2016 .

[18]  Rajarsi Mandal,et al.  Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. , 2016, Cancer Discovery.

[19]  C. Klein,et al.  A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells , 2016, Molecular Cancer Therapeutics.

[20]  Gregory J. Chen,et al.  Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma. , 2016, Biochemical and biophysical research communications.

[21]  S. Antonarakis,et al.  Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma , 2016, Nature Genetics.

[22]  A. Ribas,et al.  Combination cancer immunotherapies tailored to the tumour microenvironment , 2016, Nature Reviews Clinical Oncology.

[23]  James R. Eshleman,et al.  Microsatellite Instability as a Biomarker for PD-1 Blockade , 2016, Clinical Cancer Research.

[24]  A. Legat,et al.  Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial , 2015, Clinical Cancer Research.

[25]  A. Chang,et al.  A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma , 2015, Oncotarget.

[26]  J. Gartner,et al.  Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. , 2015, The Journal of clinical investigation.

[27]  P. Carter,et al.  Therapeutic antibodies: Discovery, design and deployment. , 2015, Molecular immunology.

[28]  F. Giles,et al.  Blinatumomab for the treatment of acute lymphoblastic leukemia , 2015, Investigational New Drugs.

[29]  Xue Han,et al.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.

[30]  I. Mercier,et al.  Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators , 2015, Front. Immunol..

[31]  H. Heslop,et al.  Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. , 2015, Blood.

[32]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[33]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[34]  P. Amrolia,et al.  CD19 chimeric antigen receptor T cell therapy for haematological malignancies , 2015, British journal of haematology.

[35]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[36]  Lisa A. Raedler.  Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma. , 2015, American health & drug benefits.

[37]  C. Klein,et al.  Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules , 2015, Cancer Immunology Research.

[38]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[39]  F. Marincola,et al.  2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond , 2015, EBioMedicine.

[40]  Sadik H. Kassim,et al.  A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response , 2014, Clinical Cancer Research.

[41]  S. Rosenberg.  Decade in review—cancer immunotherapy: Entering the mainstream of cancer treatment , 2014, Nature Reviews Clinical Oncology.

[42]  R. Gibbs,et al.  Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma , 2014, Clinical Cancer Research.

[43]  U. Brinkmann,et al.  Tumor-antigen-binding bispecific antibodies for cancer treatment. , 2014, Seminars in oncology.

[44]  Ying Tang,et al.  LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth , 2014, Clinical Cancer Research.

[45]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[46]  R. Schreiber,et al.  New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. , 2014, Current opinion in immunology.

[47]  D. Teachey,et al.  Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies , 2014, Cancer journal.

[48]  Channing J Der,et al.  KRAS: feeding pancreatic cancer proliferation. , 2014, Trends in biochemical sciences.

[49]  H. Pircher,et al.  Immunotherapy with TCR-Redirected T Cells: Comparison of TCR-Transduced and TCR-Engineered Hematopoietic Stem Cell–Derived T Cells , 2014, The Journal of Immunology.

[50]  Zoltan Szallasi,et al.  Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations , 2013, PloS one.

[51]  C. Horak,et al.  Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[53]  B. Robert,et al.  Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells , 2013, Molecular Cancer Therapeutics.

[54]  Jonathan B. Mitchem,et al.  A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma , 2013, Investigational New Drugs.

[55]  B. Shalmon,et al.  Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies , 2013, Clinical Cancer Research.

[56]  A. Borkhardt,et al.  Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic leukemia (ALL). , 2013 .

[57]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[58]  Jeffrey E. Lee,et al.  Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients , 2012, Clinical Cancer Research.

[59]  V. Sondak,et al.  Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma , 2012, Journal of immunotherapy.

[60]  W. Birchmeier,et al.  Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.

[61]  A. Krüger,et al.  The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth , 2012, Front. Pharmacol..

[62]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[63]  Marianna Sabatino,et al.  Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment , 2012, Journal of immunotherapy.

[64]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[65]  S. Rosenberg,et al.  CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.

[66]  Z. Dong,et al.  Curtailing side effects in chemotherapy: a tale of PKCδ in cisplatin treatment , 2012, Oncotarget.

[67]  C. Snyder.  Buffered memory: a hypothesis for the maintenance of functional, virus-specific CD8+ T cells during cytomegalovirus infection , 2011, Immunologic research.

[68]  M. Tsao,et al.  An overview of the c-MET signaling pathway , 2011, Therapeutic advances in medical oncology.

[69]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[70]  E. Wherry.  T cell exhaustion , 2011, Nature Immunology.

[71]  Larissa V Furtado,et al.  Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer , 2011, Genes, chromosomes & cancer.

[72]  Yanping Zhang,et al.  The role of interleukin‐12 on modulating myeloid‐derived suppressor cells, increasing overall survival and reducing metastasis , 2011, Immunology.

[73]  J. Kirkwood,et al.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.

[74]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[75]  M. Gutiérrez,et al.  First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity , 2010, Journal of Translational Medicine.

[76]  L. Luznik,et al.  High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation , 2010, Immunologic research.

[77]  D. Olive,et al.  BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. , 2010, The Journal of clinical investigation.

[78]  P. Baeuerle,et al.  Bispecific T-cell engaging antibodies for cancer therapy. , 2009, Cancer research.

[79]  Janice M Reichert,et al.  Monoclonal antibodies as innovative therapeutics. , 2008, Current pharmaceutical biotechnology.

[80]  S. Steinberg,et al.  Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines , 2008, Clinical Cancer Research.

[81]  T. Schumacher,et al.  Long-Term Functionality of TCR-Transduced T Cells In Vivo1 , 2008, The Journal of Immunology.

[82]  S. Giordano,et al.  Molecular cancer therapy: can our expectation be MET? , 2008, European journal of cancer.

[83]  S. O’Day,et al.  Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) , 2007, Cancer.

[84]  T. Schumacher,et al.  Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. , 2007, Blood.

[85]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[86]  J. Martinko,et al.  Disulfide Bond Engineering to Trap Peptides in the MHC Class I Binding Groove1 , 2007, The Journal of Immunology.

[87]  S. Rosenberg,et al.  Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. , 2007, Cancer research.

[88]  B. Robert,et al.  Active Antiviral T-Lymphocyte Response Can Be Redirected against Tumor Cells by Antitumor Antibody × MHC/Viral Peptide Conjugates , 2006, Clinical Cancer Research.

[89]  J. Madrenas,et al.  A molecular perspective of CTLA-4 function. , 2006, Annual review of immunology.

[90]  Jilin Sun,et al.  Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. , 2006, Cancer research.

[91]  V. Kuchroo,et al.  The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity , 2005, Nature Immunology.

[92]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study , 2005, Annals of Surgical Oncology.

[93]  J. Christensen,et al.  c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. , 2005, Cancer letters.

[94]  T. Blankenstein,et al.  Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. , 2005, Human gene therapy.

[95]  F. Lozupone,et al.  Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? , 2005, Expert opinion on biological therapy.

[96]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  A. Lanfranco,et al.  CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.

[98]  C. Drake,et al.  Role of LAG-3 in regulatory T cells. , 2004, Immunity.

[99]  B. Baker,et al.  Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. , 2004, The Journal of clinical investigation.

[100]  S. Fujita,et al.  Existence of Leukemic Clones Resistant to Both Imatinib Mesylate and Rituximab before Drug Therapies in a Patient with Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia , 2004, International journal of hematology.

[101]  Avital Lev,et al.  Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[102]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[103]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[104]  M. J. Abedin,et al.  Possible role of galectin‐9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance , 2002, International journal of cancer.

[105]  F. Marincola,et al.  A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma , 2002, Journal of immunotherapy.

[106]  L. Lybarger,et al.  Cutting Edge: Single-Chain Trimers of MHC Class I Molecules Form Stable Structures That Potently Stimulate Antigen-Specific T Cells and B Cells1 , 2002, The Journal of Immunology.

[107]  R. Salgia,et al.  Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. , 2002, Cytokine & growth factor reviews.

[108]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[109]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[110]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  J. Bluestone,et al.  Regulation of CTLA-4 expression during T cell activation. , 1996, Journal of immunology.

[112]  R. Fisher,et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[114]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[115]  A. Bardelli,et al.  Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. , 1991, The EMBO journal.

[116]  S. Rosenberg,et al.  In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. , 1987, Cancer research.

[117]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[118]  S. Rosenberg,et al.  In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. , 1985, Journal of immunology.

[119]  A. Chang,et al.  The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. , 1984, Journal of immunology.

[120]  R. North,et al.  T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor , 1980, The Journal of experimental medicine.

[121]  R. Scolyer,et al.  Resistance to PD1/PDL1 checkpoint inhibition. , 2017, Cancer treatment reviews.

[122]  Yanping Xiao,et al.  The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. , 2015, Cancer discovery.

[123]  J. Kaye,et al.  References Subscriptions Permissions Email Alerts An Inhibitory Ig Superfamily Protein Expressed by Lymphocytes and APCs Is Also an Early Marker of Thymocyte Positive Selection , 2013 .

[124]  C. Melief,et al.  Cancer immunology. , 2011, Current opinion in immunology.

[125]  P. Chames,et al.  Bispecific antibodies for cancer therapy: the light at the end of the tunnel? , 2009, mAbs.

[126]  Antonio Polley,et al.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.

[127]  Randall J Lee,et al.  The new face of bispecific antibodies: targeting cancer and much more. , 2006, Experimental hematology.

[128]  C. Ware,et al.  B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator , 2005, Nature Immunology.

[129]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[130]  S. Kaye,et al.  New antimetabolites in cancer chemotherapy and their clinical impact. , 1998, British Journal of Cancer.

[131]  A. McMichael,et al.  Edinburgh Research Explorer Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets , 2022 .